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AbstrAct:
Molecular chaperones are master regulators of protein folding quality control, 
and it is widely accepted that these functions are aberrantly exploited in 
human tumors. What has also emerged in recent years is that chaperone 
control of protein folding does not occur randomly in cells, but is spatially 
compartmentalized in subcellular organelles and specialized microenvironments. 
Fresh experimental evidence has now uncovered a role for mitochondrial localized 
chaperones to oversee the protein folding environment within the organelle, 
selectively in tumor cells. Perturbation of this compartmentalized chaperone 
network triggers an array of compensatory responses that aims at restoring 
homeostasis, while also providing novel opportunities for rational cancer therapy.
INtrODUctION
Built on a better understanding of cancer genes and 
their pathways [1], it is now possible to encompass cancer 
signaling pathways in their globality, as orchestrated, 
interconnected  networks. Taking advantage of systems 
biology tools [2], this approach may be better suited to 
capture the complexity of tumor cells, and account for 
typical traits of malignant growth, such as heterogeneity, 
redundancy, and buffering [3]. The charting of network 
connectivity maps [2] may also uncover the function of 
so-called nodal proteins in tumors, hub molecules that 
control multiple downstream subnetworks, and whose 
therapeutic inhibition may provide desirable anticancer 
activity in genetically and molecularly heterogeneous 
tumors.
Molecular chaperones neatly fulfill the definition of 
cancer nodal proteins [4]. Fueled by the energy produced 
by ATP binding and hydrolysis, and assembled as 
supramolecular protein complexes, molecular chaperones, 
especially members of the Heat Shock Protein (Hsp) 
family, oversee the global process of protein folding 
quality control, impinging in virtually every aspect of 
cellular homeostasis [4]. We also know that chaperone 
control of protein folding does not occur randomly in 
cells, but is compartmentalized in subcellular organelles 
and specialized microenvironments. The list of these 
sites has grown considerably over the years, and now 
includes the endoplasmic reticulum (ER), mitochondria, 
nuclei, the plasma membrane and even the extracellular 
environment [4].
Now, recent evidence suggests that the mitochondrial 
pool of molecular chaperones [5] maintains the organelle 
protein folding environment in tumor cells, and is hard-
wired to the transcriptional stress response machinery of 
cell adaptation and cell survival [6].
MItOcHONDrIAL cHAPErONEs 
IN tHE cONtrOL OF tUMOr cELL 
sUrVIVAL
Results from our group recently uncovered a 
network of molecular chaperones that localize to 
mitochondria, almost exclusively in tumor cells [7]. 
For some of these molecules, for instance the Hsp90 
homolog, TNF Receptor-Associated Protein-1 (TRAP-
1) [5], and the chaperonin Hsp60 [8], a mitochondrial 
localization had been described before, and either linked 
to unknown functions or the refolding of proteins that 
cross the mitochondrial membrane, respectively. Instead, 
a mitochondrial pool of Hsp90 had not been previously 
described, anticipating a broader role of this chaperone 
in organelle homeostasis [5]. It is still unclear how Hsp90 
accumulates preferentially in mitochondria of tumor cells, 
compared to normal tissues, but earlier work suggested a Oncotarget 2011; 2:  347 - 351 348 www.impactjournals.com/oncotarget
potential role of oncogenic signaling, but not metabolic 
unbalance, in this pathway [5].
Once in mitochondria, Hsp chaperones form a 
physical complex with cyclophilin D (CypD) [5], an 
immunophilin component of the organelle permeability 
transition pore, or at least a pivotal regulator of it [9]. 
A detailed structure-function relationship of CypD-
chaperone complex(es) is still missing, but there is initial 
evidence that mitochondrial Hsp90, TRAP-1, and Hsp60 
may simultaneously bind CypD through non-overlapping 
recognition sites. In turn, the multichaperone-CypD 
complex antagonizes the opening of the mitochondrial 
permeability transition pore, potentially by protein (re)
folding, shutting off the initiation of apoptosis in tumors 
[7]. Mechanistically, this pathway appears ideally 
suited to globally elevate the anti-apoptotic threshold in 
transformed cells [7], favoring the acquisition of additional 
malignant traits, including adaptation to unfavorable, i.e. 
hypoxic, environments, and resistance to conventional or 
targeted therapy.
For this reason, mitochondrial Hsp chaperones 
provide attractive targets for cancer therapeutics. 
Embodying the concept of subcellularly-targeted therapy 
for human diseases, a novel class of small molecule 
Hsp90 inhibitors was recently engineered to target the 
chaperone pool selectively in mitochondria. When tested 
in preclinical models, these agents, called Gamitrinibs 
(geldanamycin –GA- mitochondrial matrix inhibitors) 
induced sudden collapse of organelle integrity, with 
apoptotic killing of heterogeneous tumor cell types [10], 
and inhibition of localized and metastatic tumor growth 
in mice. Because molecular chaperones are virtually 
absent, and anyway uncomplexed with CypD in normal 
mitochondria [8], Gamitrinib-based therapy was well 
tolerated, with no detectable toxicity for normal cells or 
tissues, in vivo [7].
HArD-WIrING OF MItOcHONDrIAL 
cHAPErONEs WItH tHE cELLULAr 
strEss rEsPONsE IN tUMOrs
Now, recent data have shown that Gamitrinib, 
especially the variant containing triphenylphosphonium 
as mitochondriotropic moiety [7], triggered an entirely 
new signaling pathway in tumor cells. Using glioblastoma 
as a model, it was recently shown that sub-optimal 
concentrations of Gamitrinib that have minimal or no 
effect on cell viability, dramatically activated autophagy, 
with extensive cytoplasmic vacuolation and lipidation 
of the autophagy marker, dynein light chain 3 [6] (Fig. 
1). It is still debated whether autophagy is a form of cell 
death, a survival mechanism, or both [11]. In the case 
of Gamitrinib, this pathway was clearly a compensatory 
response aimed at maintaining cell viability, as 
pharmacologic inhibitors of phagosome formation or small 
interfering RNA (siRNA) knockdown of the essential 
autophagy gene, atg5, converted non-toxic concentrations 
of Gamitrinib into active doses that killed glioblastoma 
cells by apoptosis [6].
Second, mitochondria isolated from glioblastoma 
cells treated with low concentrations of Gamitrinib 
showed accumulation of unfolded, i.e. insoluble 
proteins, deregulated expression of “sensor” proteins of 
organelle damage, and a “stress response” gene signature 
characterized by upregulation of chaperones, for instance 
Hsp70, and transcription factors, CCAAT-enhancer 
binding  protein,  C/EBPβ,  and  its  dimerization  partner, 
CHOP [6] (Fig. 1). Together, these are all markers of a 
mitochondrial unfolded protein response (UPR) [12-14], 
and genetic knockdown of the targets of Gamitrinib in 
Figure 1: bipartite mitochondrial UPr induced by targeting organelle Hsp chaperones. Treatment of tumor cells with low, i.e. 
non-cytotoxic concentrations of mitochondrially-targeted Hsp90 inhibitor, Gamitrinib induces a proteotoxic response within accumulation of 
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mitochondria, TRAP-1 or CypD, reproduced this pathway 
independently of pharmacologic inhibition. Intriguingly, 
one of the hallmarks of this mitochondrial UPR was a 
complete ablation of NFκB transcriptional activity, either 
constitutive or in response to TNFα, with concomitant 
loss of multiple downstream NFκB-inducible genes [6] 
(Fig. 2). The suppression of NFκB activity under these 
conditions was mediated by upregulated CHOP and C/
EBPβ, but was not part of a general inhibitory effect on 
gene expression, and was specific for the mitochondrial 
chaperones, as a non-subcellularly-targeted Hsp90 
inhibitor, 17-AAG, had no effect [6] (Fig. 2).
There is a wealth of literature pointing to a pivotal 
role  of  NFκB  in  tumor  progression.  In  addition  to 
modulating  an  inflammatory  tumor  microenvironment, 
NFκB  functions  as  a  potent  survival  mechanism  in 
tumors, upregulating the expression of multiple anti-
apoptotic genes, including cFLIP, a negative regulator of 
death receptor-induced apoptosis [15]. This response has 
important implications in the clinic, because high NFκB 
activity is typically associated with treatment resistance 
and worse outcome in cancer patients. Together, this raised 
a testable hypothesis, whether tumor cells undergoing 
mitochondrial  UPR  and  concomitant  loss  of  NFκB-
activity (Fig. 2), were now re-sensitized to apoptosis-
based therapy. For these experiments, we used TNF 
Receptor Apoptosis-Inducing Ligand (TRAIL), a potent 
pro-apoptotic death receptor ligand currently in clinical 
trials, but whose efficacy is often reduced or abolished 
by  NFκB.  Instead,  a  combination  regimen  of  low,  i.e. 
non-cytotoxic concentrations of Gamitrinib plus TRAIL 
dramatically killed tumor cells normally resistant to 
TRAIL, and potently inhibited intracranial glioblastoma 
growth in mice with no detectable toxicity [6].
UNANsWErED QUEstIONs AND 
FUtUrE DIrEctIONs
Overall, these data [6] open fresh perspectives 
into how tumor cells cope with compartmentalized, i.e. 
mitochondrial proteotoxic stress, and mount a multipartite 
response that attempts to preserve cell survival and 
restore homeostasis (Fig. 1). Much of our knowledge 
about organelle-initiated UPR comes from studies of ER 
damage [16]. In contrast, the nature of a mitochondrial 
UPR has remained largely elusive, complicated by the 
unique architecture of the organelle, its production of 
protein-altering reactive oxygen species, and the dual role 
of matrix proteases and chaperones in preprotein import 
and (re)folding [17]. Although we knew that artificially-
induced mitochondrial damage could lead to an UPR 
[12-14], what we did not know were the physiologic 
requirements of this pathway, and its broader implications 
for cellular homeostasis. The recent results [6] now suggest 
that a mitochondrial UPR may be a relatively common 
occurrence in tumors that undergo non-fatal mitochondrial 
damage, and identify mitochondrial Hsp chaperones as 
physiologic mediators of this response. It is also clear that 
not all mitochondrial damage induces an UPR, because 
organelle outer membrane depolarization, or induction of 
apoptosis had no effect [6]. As to the functional question 
whether this response is friend or foe, it seems reasonable 
to speculate that the combined activation of autophagy 
and stress response genes (Fig. 1) provide a powerful 
compensatory mechanism to eliminate the damaged 
organelles, while globally elevating the cell’s buffering 
and survival threshold, respectively [17]. We still do not 
know how this combined adaptive and cytoprotective 
mechanism becomes so dramatically exploited in cancer 
[5]. A possible model is that tumor cells hijack this response 
from a normal counterpart, and, in this case, neurons 
are interesting candidates for potential exploitation, as 
these cells rely on cytoprotection from mitochondrial 
Hsps to antagonize CypD-dependent apoptosis [18], and 
preserve cell survival [19]. Although activation of the 
mitochondrial UPR [6] may worsen disease outcome, 
similar to how other stress response mechanisms facilitate 
tumor progression [20], the profound suppression of 
NFκB seen under these conditions [6], may open concrete 
opportunities to re-sensitize resistant tumors to apoptosis-
inducing agents, a critical goal of modern cancer therapy 
Figure 2: Exploitation of a mitochondrial UPr for cancer therapy. Mitochondrial dysfunction associated with proteotoxic stress 
results in the upregulation of stress response transcription factors, CHOP and C/EBPβ, which in turn repress NFκB activity, sensitizing tumor 
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[21] (Fig. 2).
Clearly, important questions remain to be answered. 
First, it is unclear how inhibition of mitochondrial 
Hsp90s, and the ensuing organelle proteotoxic stress 
(Fig. 1), couple to nuclear activation of gene expression. 
Examples from other organelle-initiated stress response 
pathways may help pointing to future experiments 
[22], and second messengers potentially generated by 
changes in mitochondrial bioenergetics, deregulated 
Ca2+ homeostasis or intramitochondrial proteolysis may 
be explored as effectors of this response [23]. A second 
important question is whether the signal generated through 
the mitochondrial UPR requires amplification by the ER 
stress-sensing machinery to fully activate gene expression. 
The concept of inter-organelle communication is emerging 
more and more often in disparate experimental systems, 
and, in particular, ER and mitochondria share extensive 
areas of physical contact, populated by an elaborate stress-
sensing machinery that couples to gene expression. And, 
finally, there is the question of how this mitochondrial UPR 
actually represses NFκB activity, when other organelle 
signaling pathways are instead typically associated with its 
induction [16, 24]. Here, it will be of interest to test a link 
between the transcriptional effectors of the mitochondrial 
UPR and the plethora of NFκB activators or inhibitors 
that control the balance between induction and silencing 
of this pathway, especially in tumor cells.
For now, the recent results [6] have uncovered a 
new layer of complexity for how tumor cells adjust to 
their aberrantly higher biosynthetic needs, and control 
the mitochondrial protein folding environment against 
the risk of proteotoxic stress (Fig. 1). The recent proof-
of-concept studies [6] reinvigorate the concept of 
Hsp90 chaperones as important nodal targets for cancer 
therapeutics, but also underscore that only targeting their 
inhibitors to specialized subcellular microenvironments, 
for instance mitochondria [7], can achieve the kind of 
anticancer  efficacy  that  bodes  well  for  human  testing. 
And, finally, it is now possible to envision molecularly-
grounded synergistic anticancer therapies, exemplified by 
the combination of Gamitrinib plus TRAIL, which turn the 
table on a general adaptive and survival mechanism (Fig. 
2) to deliver promising activity in models of notoriously 
recalcitrant human tumors.
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